Fennec Pharmaceuticals ( (TSE:FRX) ) has provided an update.
Fennec Pharmaceuticals reported a 40% increase in full-year net product sales for PEDMARK® in 2024, reaching $29.6 million, with significant growth in the adolescent and young adult segment. The company has made strategic moves to strengthen its financial position, including early repayment of $13 million of its convertible debt, and expanded its market reach with the commercial launch of PEDMARQSI® in the UK and Germany, positioning itself for further growth in 2025.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of ototoxicity, particularly in the adolescent and young adult segment. The company has expanded its market presence with products like PEDMARK® and PEDMARQSI® in the United States and Europe, targeting cancer patients at risk of hearing loss.
YTD Price Performance: 2.23%
Average Trading Volume: 78,725
Technical Sentiment Signal: Hold
Current Market Cap: $181.8M
For a thorough assessment of FRX stock, go to TipRanks’ Stock Analysis page.